IMMUNOGLOBULIN A NEPHROPATHY
Clinical trials for IMMUNOGLOBULIN A NEPHROPATHY explained in plain language.
Never miss a new study
Get alerted when new IMMUNOGLOBULIN A NEPHROPATHY trials appear
Sign up with your email to follow new studies for IMMUNOGLOBULIN A NEPHROPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for kidney disease: drug shows promise in slowing damage
Disease control OngoingThis study tested a new drug called sparsentan for people with IgA nephropathy, a kidney disease that can lead to kidney failure. About 400 adults took either sparsentan or a standard blood pressure medication for about 2 years. The goal was to see if sparsentan could better prot…
Matched conditions: IMMUNOGLOBULIN A NEPHROPATHY
Phase: PHASE3 • Sponsor: Travere Therapeutics, Inc. • Aim: Disease control
Last updated Jun 15, 2026 19:05 UTC
-
New drug aims to slow kidney damage in IgA nephropathy patients
Disease control OngoingThis study tests an investigational drug called povetacicept in about 605 adults with IgA nephropathy, a kidney disease. The goal is to see if it can reduce protein in the urine and preserve kidney function better than a placebo. Participants must have a confirmed diagnosis and s…
Matched conditions: IMMUNOGLOBULIN A NEPHROPATHY
Phase: PHASE3 • Sponsor: Alpine Immune Sciences Inc, A Subsidiary of Vertex • Aim: Disease control
Last updated Jun 11, 2026 12:09 UTC